Please stand by. Good day, ladies and gentlemen. Welcome to the second quarter 2023 earnings conference call for Venus Concept. At this time, all participants have been placed in a listen-only mode. Please note that this conference call is being recorded, and the recording will be available on the company's website for replay. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the Risk Factors section of our most recent 10-Q and our annual report on Form 10-K filed with the Securities and Exchange Commission. Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events, or otherwise. This call will also include references to certain financial measures that are not calculated in accordance with Generally Accepted Accounting Principles, or GAAP. We generally refer to those as non-GAAP financial measures. Reconciliation of those non-GAAP financial measures to the most comparable measures, calculated and presented in accordance with GAAP, are available in our earnings press release, issued today on the investor relations portion of our website. I would now like to turn the call over to Mr. Rajiv De Silva, Chief Executive Officer of Venus Concept. Please go ahead, sir. Thank you, operator, and welcome everyone to Venus Concept's second quarter 2023 earnings conference call. I'm joined on the call today by our Chief Financial Officer, Domenic Della Penna, and by our President and Chief Innovation and Business Officer, Dr. Hemanth Varghese. Let me start with an agenda of what we will cover during our prepared remarks. I will begin with a brief overview of our Q2 results and notable operating developments in recent months. Hemanth will share an update on our recent progress in our restructuring programs, R&D priorities, and new product pipeline progress, as well as our recently announced formation of a medical advisory board. Domenic will then provide you with an in-depth review of our second quarter financial results and our balance sheet and financial condition at quarter end, as well as a review of our 2023 financial guidance, which we reaffirmed in today's press release. We will open the call for your questions. With that agenda in mind, let's get started. As you would have seen in our press release issued today, in the second quarter of 2023, we delivered total revenue of $20.1 million. These results are within the range of expectations we provided on our Q1 earnings call. Our second quarter revenue results reflect notable declines versus the prior year, as expected. Similar to what we discussed on our Q1 call, the year-over-year revenue decline is a direct result of the strategic initiatives we are executing this year. Specifically, we are transitioning the company to higher quality revenues, exiting unprofitable direct operations in certain international markets, and implementing a series of restructuring activities, which together are expected to enhance the cash flow profile of the business and to accelerate the path to long-term sustainable profitability and growth. Our results in Q2 point to continued progress towards these key strategic initiatives that we outlined earlier this year. First, we are pleased to report that cash system sales represented 74% of total system sales and subscription sales, compared to 49% in the prior year period. Our progress towards this initiative is even more evident when looking at the mix of cash system sales in the US, which represented 82% of total US systems and subscription sales in Q2, compared to 36% in the prior year period. Cash system sales to US customers increased 55% year-over-year in Q2, and as expected, this growth fueled significant improvements in our cash generation, given the higher quality of revenue cash system sales represent. Second, our restructuring activities continue to progress. We are right-sizing the business, reducing costs, and simplifying the organization. We delivered a 25% reduction in our non-GAAP operating expenses, representing a reduction of $6.5 million year-over-year. Our progress in each of these areas in Q2 drove a 71% reduction in cash used in operations on a year-over-year basis, and a 64% reduction in cash used in operations on a quarter-over-quarter basis. We believe this represents the clearest evidence that we are on the right track towards our goal of enhancing the cash flow profile of the business and accelerating the path to long-term sustainable profitability and growth. We are particularly pleased with our performance in light of a very difficult financing environment for our end customers. This is, this is even more relevant considering our shift from subscription revenues to higher quality cash system sales that rely on third-party financing for our customers. The inflationary economy has impacted higher price procedures, such as those related to our hair business. There are two other items I wanted to briefly discuss. First, we remain highly focused on maximizing our capital resources as we work to manage our near to intermediate term debt obligations and to further enhance the company's foundation for achieving our longer term goals. As outlined on our recent calls, our strategic plan originally targeted a reduction in the company's cost structure by a total annual pre-tax savings of $13 million-$15 million, beginning in 2024, and achieving cash flow breakeven in the second half of 2024. We're evaluating a series of incremental initiatives to continue our path to cash flow breakeven in the second half of 2024, without impacting our 2023 objectives. We are also actively engaged in discussions with key lenders to ensure the requisite runway that allows us to execute our strategic plan and successfully achieve cash flow breakeven next year. We are appreciative of the constructive relationship that we have, that we have with our primary lenders. Second, we developed a plan for regaining NASDAQ continued listing compliance, which was approved by the exchange. NASDAQ provided us with an extension of the compliance period through November 2023. I would now like to turn the call over to Dr. Hemanth Varghese, who will share an update on recent progress in our restructuring programs, R&D investments, and new product pipeline initiatives, including our recently announced formation of a medical advisory board. Hemant? Thanks, Rajiv. As Rajiv described earlier, we've already made considerable progress against several key initiatives of our corporate turnaround strategy. On balance, we believe we are executing the strategic plan we outlined at the start of the year on or ahead of expectations. Let me share a little color in key areas where we are making notable progress. First, our cost reduction and cash management initiatives designed to accelerate our path to cash flow breakeven, are progressing at or ahead of expectations. It is a credit to the hard work and dedication of the entire Venus Concept organization, who have all greatly contributed to improving business performance. In addition, during Q2, we made the decision to target additional cost containment initiatives, including identifying areas where we can implement phased R&D investments to protect cash runway and accelerate our path to cash flow breakeven. Second, recognizing the challenging environment that many of our customers are facing, we've taken proactive steps to stay responsive to market headwinds and are implementing plans in the US and internationally to provide greater commercial momentum as we move through the balance of 2023. We have initiated several targeted programs to provide more operational flexibility to our commercial teams, including new financial tools and transaction support, needed to provide an enhanced level of customer and deal support. We believe that these measures will enhance overall sales productivity while improving our ability to respond to an evolving market conditions. In the U.S., we're streamlining our internal financing processes, expanding our capacity to perform on-site demos, introducing new sales promotions and incentive programs, as well as enhancing our level of technical service commitments to our customers. Outside the U.S., our efforts to right size the business are progressing well. We are rationalizing our international infrastructure, reducing costs, and simplifying the organization with a keen focus on establishing the optimal mix of direct presence and distribution partners in key international markets around the world. Third, as mentioned earlier, while refocusing our R&D efforts has resulted in phasing of some project spend to better manage cash burn, we've also been able to leverage our broad portfolio of technology and IP to advance certain new product pipeline projects ahead of expectations. Specifically, we now expect FDA 510(k) clearance in the third quarter and initial commercial introduction in the fourth quarter of a new medical device aesthetic system, the VersaPro. The VersaPro is the next generation version of the Venus Versa, one of the company's flagship products, with more than 2,500 systems sold globally since introduction. The VersaPro is our second generation Versa that leverages our novel (MP)², IPL, and NanoFractional RF technology that treats color, texture, and tightening for the face and body with a choice of 10 hand pieces. We're adding the advances that have been made with Viva MD to provide higher power and deeper skin penetration for optimal results. We see this as an important near-term growth opportunity for new customers and an attractive upgrade opportunity for existing customers. We are proud of the R&D team's strong execution and commitment to our goals, which resulted in an accelerated product development process. The team has us poised for an exciting new product introduction in the fourth quarter of 2023, ahead of our original timeline. Our new product pipeline continues to progress favorably in terms of what we expect in 2024 as well. Specifically, we are on an accelerated plan for the commercial introduction of our next body system in the first half of 2024. Importantly, we are encouraged by the continued progress we are making in support of our target for commercial introduction of the AI.ME, our next generation aesthetic robotics platform in the second half of 2024. As announced last month, we are very excited to have established our new medical advisory board for AI.ME. We are fortunate to have attracted the support of an industry-leading group of physicians to help us realize AI.ME's full potential clinically. We look forward to engaging with this group to initiate a series of clinical studies over the next several months. These studies are designed to inform our AI.ME Aesthetic robotic robotics product development and clinical strategy, ensuring we continue to meet the evolving needs of patients and providers with advanced technologies and strong clinical impact. Our first three AI.ME systems for clinical use have been built and will be shipped to kick off initial study activities in Q3. It is important to note that we expect the commercial launch of AI.ME to be consistent with the 510(k) clearance we received in December of 2022. No further FDA clearances are required to support the commercial launch planned for H2 2024. With that, let me turn the call over to Dominic for a review of our second quarter financial results and balance sheet as of June 30th. Dominic? Thanks, Hemanth. For the avoidance of doubt, unless otherwise noted, my prepared remarks will focus on the company's reported results for the second quarter of 2023 on a GAAP basis, and all growth-related items are on a year-over-year basis. We reported GAAP revenue of $20.1 million, down 26% year-over-year. The decrease in total revenue by region was driven by a 27% decrease year-over-year in US revenue and a 26% decrease year-over-year in international revenue. The decrease in total revenue by product category was driven by a 64% decrease in lease revenue and a 16% decrease in products other revenue, offset partially by a 7% increase in product systems revenue and a 13% increase in services revenue. Turning to a review of our second quarter financial results across the rest of the P&L, gross profit decreased $4.8 million, or 25%, to $14.2 million. The change in gross profit was driven primarily by the year-over-year decline in revenue in the United States and international markets, driven by the strategic decision to focus on quality of revenue by de-emphasizing subscription sales and exiting and/or rightsizing unprofitable direct markets. Gross margin was 70.8%, compared to 69.9% of revenue in the second quarter of 2022. The change in gross margin was primarily due to changes in product mix, including, including lower ARTAS system sales, which have a lower gross margin than our energy-based devices, partially offset by a $0.2 million foreign exchange headwind as a result of certain currencies depreciating relative to the US dollar. Total operating expenses decreased $6.2 million, or 24%, to $20 million. The change in total operating expenses was driven primarily by a decrease of $3.3 million, or 26%, in general and administrative expenses, a decrease of $2.1 million, or 20%, in sales and marketing expenses. Second quarter of 2023 GAAP general and administrative expenses include approximately $0.4 million of costs related to restructuring activities designed to improve the company's operations and cost structure. Excluding these restructuring costs, our non-GAAP operating expenses declined $6.6 million, or 25%, year-over-year. Excluding the aforementioned non-GAAP items and non-cash D&A, stock compensation expense, and bad debt expenses in both periods, our non-GAAP cash operating expenses declined $4.2 million, or 19%, year-over-year. The total operating loss was $5.8 million, compared to $7.1 million in the second quarter of 2022. Net interest and other expenses were $1.4 million, compared to $3.4 million in the second quarter of 2022. The year-over-year change in net interest and other expenses was driven by non-cash foreign exchange gain loss, which was a $178,000 gain in the second quarter of 2023, compared to a loss of $2.4 million last year. Net loss attributable to stockholders for the second quarter of 2023 was $7.4 million, or $1.35 per share, compared to $10.6 million, or $2.47 per share, for the second quarter of 2022. Note, our net loss per share calculations in the current and prior year periods reflect the 1-for-15 reverse stock split in May 2023. Adjusted EBITDA loss for the second quarter of 2023 was $4 million, compared to $5.5 million for the second quarter of 2022. As a reminder, we have provided a full reconciliation of our GAAP net loss to adjusted EBITDA loss in our earnings press release. Turning to the balance sheet. As of June 30th, 2023, the company had cash and cash equivalents of $6.1 million and total debt obligations of approximately $78.4 million, compared to $11.6 million and $77.7 million, respectively, as of December 31st, 2022. Cash used in operations for the three months ended June 30th was $2.1 million, a 71% decrease in cash use year-over-year. The improvement in cash used in operations was driven by our restructuring plan efforts, improvements in working capital, and the benefits to our cash flow generation as a result of our initiative to focus on cash system sales, including a significant reduction in bad debt expense, tracing to tighten credit screening practices for subscription sales in an otherwise challenged credit market. Cash used in operating and investing activities during the second quarter of 2023 was partially offset by $1.9 million of cash from financing activities in the period, driven by the net proceeds of $1.6 million from the sale of senior preferred stock from the 2023 multi-tranche private placement, which occurred on May 15th, 2023, and proceeds from the issuance and sale of common stock pursuant to our equity purchase agreement with Lincoln Park Capital of $0.3 million. Turning to a review of our guidance. As detailed in our press release, we reaffirmed our revenue guidance for the full year 2023 period. The company continues to expect total revenue for the 12 months ending December 31, 2023, in the range of $90 million-$95 million, representing a decrease in the range of approximately 9.5%-4.5% year-over-year. While we are not providing formal profitability guidance for the full year 2023, we are providing the following modeling considerations for use in evaluating our outlook for 2023. First, the 9.5% decline in revenue at the low end of our full year guidance range continues to assume total revenue growth in the second half of 2023, offset by year-over-year declines in revenue in the first half of 2023, as we complete the transition to quality of revenues. Note, the low end of our guidance implies high single-digit growth year-over-year in the second half of 2023, driven primarily by cash system sales growth of more than 30% year-over-year. We expect cash system sales to represent more than 70% of total subscription and system sales for full year 2023, compared to approximately 58% for full year 2022. Our total revenue guidance for 2023 continues to reflect year-over-year headwinds to our revenue growth from lower lease revenue in favor of cash system sales of approximately $16 million, and the impact related to the aforementioned strategic changes we are implementing in our international business this year of approximately $8 million. Excluding the impacts from prioritizing cash system sales and the strategic changes in certain international markets this year, we believe our total revenue growth would be 15% year-over-year on a normalized basis. Second, our full year 2023 revenue guidance includes the assumption that our third quarter total revenue will be in the range of $20 million-$22 million. Third, at the low end of our full year 2023 revenue range, we now expect gross margins of approximately 67%, up roughly 100 basis points year-over-year, as compared to prior guidance assumptions, which called for relatively flat gross margins year-over-year in 2023. Based on the better-than-expected expense performance in the first half of 2023, we now expect GAAP operating expenses in the range of approximately $87 million-$89 million, compared to our prior guidance of $89 million-$91 million. Note, this updated GAAP operating expense guidance range includes approximately $1.9 million of restructuring, severance, and other non-operating expenses. The updated GAAP operating expense guidance range also includes approximately $9 million of non-cash expenses, including stock compensation, D&A, and bad debt expenses. Excluding the aforementioned non-operating items and non-cash expenses, we now expect our cash operating expense target to be approximately $77 million-$79 million for 2023, down $1 million from our prior guidance range, driven by better-than-expected performance in Q2. Fourth, we continue to expect interest expense of approximately $6 million. Finally, our total revenue guidance for 2023 and our supporting modeling assumptions across the P&L are now expected to result in a reduction in our cash used from operations of more than 50% year-over-year, compared to our prior modeling assumption, which called for a reduction of more than 40% year-over-year. With that operator, we will now open the call to your questions. Operator? Thank you. If you would like to ask a question, please signal by pressing star one on your telephone keypad. If you're using a speakerphone, please make sure your mute function is turned off to allow your signal to reach our equipment. We do ask that you limit yourself to one question and one follow-up. If you would like to ask additional questions, we invite you to add yourself to the queue again by pressing star one. One moment, please. Our first question comes from Jeff Cohen with Ladenburg Thalmann. Please proceed with your question. Oh, hi, Rajiv, Dominic, and Heymanth. How are you? Hey, Jeff, we're well, thank you. Hey, Jeff. I'm gonna work backwards on a complicated question. I guess Dominic, lastly, the 87-89 OpEx in that back half, as you compare it to the previous 91-ish, and then you talk about the cash OpEx, 77-79. Guess I'm just trying to correlate the differential between cash and GAAP. Sounds like 10-12-ish, approximately. Maybe could you tie that into trimming of the business as far as OpEx and spend, and let us know how you're thinking about whether you're, you're, you're mostly through that process, or preliminary through that process, or mostly concluded through that process? Thank you. I mean, first off, Jeff, the difference between the two metrics, primarily $4 million of D&A, $2 million of stock comp expense, and about $2.5 million of bad debt expense. Those are the key drivers between the GAAP and the non-GAAP, and then the cash piece. In terms of where we stand, we're primarily through our restructuring efforts as far as they, you know, as far as what we announced earlier in the year. There is some ongoing tweaking that goes on as we continually adjust and look for opportunities. Largely, the bulk of it is behind us, subject to certain modifications that we may make as we continue to sort of unleash our strategy in the second half. Jeff, I think we will, we will continue to make some further adjustments, particularly in our international regions. That's, you know, taking a little bit longer than the changes that we made in in North America and Israel. Okay, got it. Just follow up on the technological side. The Venus Versa Pro, what, what, what difference versus the Venus Versa system now? Is it form factor, hand pieces and potentially cost of goods? Also, follow us up with, you mentioned body system. I'm assuming you were referring to the AI.ME system? With Venus Versa Pro, we'll have more on that very soon. Again, we're expecting the 510(k) clearance in the third quarter. Yes, this is what you'd expect in terms of an upgrade to any of our energy-based systems. There will be industrial design updates as well as feature updates. Bringing some of the technology that we developed for our Venus Viva MD in the NanoFractional RF onto the Versa system, which it didn't have previously, are the key updates we can speak to at this time. With respect to the body system, AI.ME is actually incremental to what we're doing with the AI.ME system, right? AI.ME, we're expecting to have come out in H2 of next year. The new body system, which again, we'll have more detail on in upcoming calls, will actually be an update to our energy-based systems with a new body system next year. Got it. Okay, that does it for us. Thanks for taking the questions. Thanks, Jeff. Thank you. Our next question comes from Marie Thibault with BTIG. Please proceed with your question. Good evening. Thank you for taking the questions. Wanted to ask one here. I heard you mention, you know, targeted programs to try to provide financial tools and transaction support to your sales teams as they go out to the U.S. and, and, and try to help those customers who are maybe facing tougher financing environments. Can you give us a little more detail on, on what sort of tools will be offered, and anything we should be considering as we think about your balance sheet and we think about those financing tools? Yeah. Marie, let, let me just provide a high-level answer to that and allow Hemant to add some detail. Look, there's, there's nothing here that should create any major impact on our, on our balance sheet. These are operational tools and techniques that we are helping our, our field force with. Some of them have to do with how we price our products, you know, particularly in combination with, with, in, in, in bundles. We've obviously also learned quite a bit about how to approach internal financing, well, given our heritage in, in, in the subscription sales model, which obviously we have tweaked and changed quite a bit. And so those are the types of tools that we are providing our field force. Nothing that should impact our balance sheet, but maybe Hemant, if you want to add any further detail. Yeah, no, I, I think you said it right. There's nothing here that would be fundamental shift in terms of our balance sheet or profitability. Think of it in terms of anything that would either help speed up or accelerate the close of any type of transaction, right? In a tough financing environment, these things take a long time to do. We've expanded our demo capacity in terms of being able to do on-site demos. As Rajiv mentioned, we've taken a look at our internal processes around our internal financing and to see if there's ways to streamline that, so we can get to decisions faster. Pricing incentives, bundles, all tools that give the field force and leadership of the commercial organization what they need to be able to move quickly when transactions are available. Okay. Just to clarify, there wouldn't be any change to revenue recognition. Everything would be recognized upfront? None. No. Yeah, no changes. Okay, perfect. Wanted to ask about. I think on an earlier call, you talked about potential partnering on the R&D side. Certainly seems like you're doing quite well going it alone for now. What might we hear on that? When might we hear more about partnering and which specific systems might you be partnering on? The, you know, look, I think, Marie, we are, we continue to be open to the concept of partnering, but our, you know, we have a lot of intellectual capital built into particularly our AI.ME system, and we wanna make sure that we advance it as much as possible under our own steam, right? That's really what we're focused on. As we have described on other calls, there are, you know, multiple ways in which the AI.ME system could evolve in the future with new indications. Once we get beyond, you know, getting our arms really wrapped around our initial launch, we certainly would benefit from other partnerships. There's, there's really no timeline to this, but we certainly remain open to the idea of partnering if it'll allow us to advance some of our future iterations of AI.ME. Okay, very helpful. Thanks for taking the questions. Thank you, Marie. Thank you. Our next question comes from Anthony Vendetti with Maxim Group. Please proceed with your question. Thanks. Yes, Vendetti. Just on, in terms of, ARTAS, what do you think the reason is for the softer sales from ARTAS? Then if you could talk about, I know you're moving away from more of the subscription business, although not completely ending it, if that's what a customer wants to do. What is the split now in terms of subscription versus purchase, outright purchase? What do you think is the ideal mix going forward? Sure, Anthony. Let me, we'll start with the ARTAS question. I think, look, I think there are a couple of reasons driving the softness in the ARTAS business, and as we described in our script. One, look, it is one of our higher priced devices, right? What we are finding is that any device that's priced above $200,000, it just becomes incrementally harder, and it takes longer for customers to get financing, right? The sales cycle is becoming longer. Then in terms of the actual procedure itself, it is also one of the higher, more higher priced procedures that our devices are used for, you know, being, you know, upwards of $10,000 to, to, to a customer, depending on the number of transplants that a customer is getting. What we're finding is that there is a certain softness when it comes to these higher priced procedures, right? Now, there's no indication that this is a permanent shift, but certainly it is probably a reflection of the current, you know, current inflationary economy. Hemant, any further details to add to that? No, I, I think you said exactly that. I, I do believe it's business cycles, and both at the customer level and at the consumer level, we're seeing it, but not something we see as permanent. On your second question, if you look at the quarter, we were at about 74% cash system sales versus, you know, 26% subscription sales. The U.S. was over indexed in cash system sales. As we said, it was about 82% and 18% subscription. You know, we are not trying to manage this to a particular number, but I would guess, you know, going forward, a 75/25 split is not a bad split to kind of think about for modeling purposes. What I would say, though, is that, you know, one of the advantages that we have, having, you know, done subscription sales for a very long period of time, we have a pretty good understanding of the customer profile that works for internal financing, right? What, what we expect to do is to continue to tweak the way we do our subscription sales or internal financing in a way that it becomes more effective, our bad debt expense keeps going down, and if we can do that effectively at a 75/25 split, that, that's a pretty decent split for us. Okay. Then just, just a follow-up on the ARTAS. You know, I know the price of the system has been brought down from over $300, but it's still over $200. Is there any? Do you feel there's any also competition? Is there a company called SmartGraft or a product called SmartGraft that sells for around $100K that, you know, might be somewhat of an option for some of the customers that are thinking about a robotic hair transplant system? The look, Anthony, as you pointed out, there, there are, you know, other options for customers. There's obviously also manual procedures. I, I think the, the reality, though, is for a new customer getting into this business, the robot offers a lot of benefits that other devices don't, right? Because it's, it's a, it, it's a way to overcome inexperienced techs. It provides repeatability for the, for the techniques. It still has an important role to play. You know, I wouldn't say that the, the, the, the competition is dramatically different, though I would say that, you know, as the end consumer looks for cheaper pricing, you know, some people do opt for the manual procedures, which do cost less, right? Like I said, for, for a lot, for practices getting into this, you know, for the first time, practices looking to expand their offerings, the robot is still a pretty unique offering. Okay, thanks. I will hop back in the queue. Appreciate it. Thank you, Anthony.